Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type

被引:80
作者
Higashi, Michiyo [1 ]
Yamada, Norishige [1 ]
Yokoyama, Seiya [1 ]
Kitamoto, Sho [1 ]
Tabata, Kazuhiro [1 ]
Koriyama, Chihaya [2 ]
Batra, Surinder K. [3 ,4 ]
Yonezawa, Suguru [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, Kagoshima 8908544, Japan
[2] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Epidemiol & Prevent Med, Kagoshima 8908544, Japan
[3] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem, Omaha, NE USA
[4] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Mol Biol, Omaha, NE USA
关键词
Cholangiocarcinoma; MUC16; CA125; Prognosis; PROGNOSTIC-FACTOR; EXTRACELLULAR SUPERSTRUCTURE; SURGICAL-TREATMENT; CA-125; GENE; MUC4; MUCINS; CA125; NEOPLASMS; CARCINOMA; DIAGNOSIS;
D O I
10.1159/000335164
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-ME) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multi-variate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion:The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:101 / 106
页数:6
相关论文
共 26 条
  • [1] The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinorna
    Aishima, S
    Asayama, Y
    Taguchi, K
    Sugimachi, K
    Shirabe, K
    Shimada, M
    Sugimachi, K
    Tsuneyoshi, M
    [J]. MODERN PATHOLOGY, 2002, 15 (11) : 1181 - 1190
  • [2] Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009
    Aljiffry, Murad
    Walsh, Mark J.
    Molinari, Michele
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (34) : 4240 - 4262
  • [3] OVCA (CA125) second generation: Technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease
    Cioffi, M
    Fratta, M
    Gazzerro, P
    DiFinizio, B
    Tucci, A
    Molinari, AM
    [J]. TUMORI, 1997, 83 (02) : 594 - 598
  • [4] Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm
    Dennis, JL
    Hvidsten, TR
    Wit, EC
    Komorowski, J
    Bell, AK
    Downie, I
    Mooney, J
    Verbeke, C
    Bellamy, C
    Keith, WN
    Olien, KA
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (10) : 3766 - 3772
  • [5] Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
    Gubbels, Jennifer A. A.
    Belisle, Jennifer
    Onda, Masanori
    Rancourt, Claudine
    Migneault, Martine
    Ho, Mitchell
    Bera, Tapan K.
    Connor, Joseph
    Sathyanarayana, Bangalore K.
    Lee, Byungkook
    Pastan, Ira
    Patankar, Manish S.
    [J]. MOLECULAR CANCER, 2006, 5 (1)
  • [6] DISTRIBUTION OF CA125 IN EMBRYONIC-TISSUES AND ADULT DERIVATIVES OF THE FETAL PERIDERM
    HARDARDOTTIR, H
    PARMLEY, TH
    QUIRK, JG
    SANDERS, MM
    MILLER, FC
    OBRIEN, TJ
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (06) : 1925 - 1931
  • [7] Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: Its relationship with a new morphological classification of cholangiocarcinoma
    Higashi, M
    Yonezawa, S
    Ho, JJL
    Tanaka, S
    Irimura, T
    Kim, YS
    Sato, E
    [J]. HEPATOLOGY, 1999, 30 (06) : 1347 - 1355
  • [8] Immunohistochemical study of mucin expression in periampullary adenomyoma
    Higashi, Michiyo
    Goto, Masamichi
    Saitou, Miyuki
    Shimizu, Takeshi
    Rousseau, Karine
    Batra, Surinder K.
    Yonezawa, Suguru
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2010, 17 (03) : 275 - 283
  • [9] Mucins in cancer: Protection and control of the cell surface
    Hollingsworth, MA
    Swanson, BJ
    [J]. NATURE REVIEWS CANCER, 2004, 4 (01) : 45 - 60
  • [10] Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma
    Inoue, K
    Makuuchi, M
    Takayama, T
    Torzilli, G
    Yamamoto, J
    Shimada, K
    Kosuge, T
    Yamasaki, S
    Konishi, M
    Kinoshita, T
    Miyagawa, S
    Kawasaki, S
    [J]. SURGERY, 2000, 127 (05) : 498 - 505